Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2004-03-09
2008-10-21
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S646000, C514S502000
Reexamination Certificate
active
07438931
ABSTRACT:
Provided are agents that can bind to copper, and form a tripartite complex with protein, and the use of these agents in the prevention and treatment of diseases with a vascular component, such as solid tumors. Compositions and methods for combination therapy of these diseases, including cancer, as well as therapeutic kits, are also provided.
REFERENCES:
patent: 2909541 (1959-10-01), Hugel
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4343746 (1982-08-01), Anglin et al.
patent: 4604278 (1986-08-01), Reilly et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4762705 (1988-08-01), Rubin
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4766226 (1988-08-01), Hill et al.
patent: 4952607 (1990-08-01), Sorenson et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5100885 (1992-03-01), Abrams et al.
patent: 5112598 (1992-05-01), Biesalski
patent: 5169858 (1992-12-01), Rubin
patent: 5385933 (1995-01-01), Rabinovitz et al.
patent: 5391547 (1995-02-01), Cole et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5512559 (1996-04-01), Skalkos et al.
patent: 5527533 (1996-06-01), Tso et al.
patent: 5556611 (1996-09-01), Biesalski
patent: 5563132 (1996-10-01), Bodaness
patent: 5565491 (1996-10-01), Schieven
patent: 5583153 (1996-12-01), Brahn
patent: RE35458 (1997-02-01), Azuara
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5639757 (1997-06-01), Dow et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), Van Der Linden et al.
patent: 5972922 (1999-10-01), Wilks et al.
patent: 6703050 (2004-03-01), Brewer et al.
patent: 2004/0009237 (2004-01-01), Brewer
patent: 1 234 585 (2002-08-01), None
patent: 1 107 795 (2002-11-01), None
patent: WO 00/13712 (2000-03-01), None
patent: WO 2004/009072 (2004-01-01), None
Brewer, G. “Tetrathiomolybdate anticopper therapy for Wilson's disease . . . ” J. Cell. Mol. Med. (2003) vol. 7, No. 1, pp. 11-20.
Elner, S. et al “Effects of tetrathiomolybdate in a mouse model . . . ” Invest. Ophthalmol. Vis. Sci. (2005) vol. 46, No. 1, pp. 299-303.
Allen and Solomons, “Normal intestinal mechanisms in the absorption of copper,” In:Absorption and Malabsorption of Mineral Nutrients, Solomons and Rosenberg, Eds., Alan R. Liss, Inc., New York, 12:199-229, 1984.
Alpern-Elran and Brem, “Angiogenesis in human brain tumors: inhibition by copper depletion,”Neurological Surgery, pp. 498-500, publication date unknown.
Brem et al., “Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain,”Neurosurgery, 26:391-396, 1990.
Hill et al., “Treatment of Wilson's disease with zinc, I: oral zinc therapy regimens,”Hepatology, 7:522-528, 1987.
Hourani and Demopoulos, “Inhibition of S-91 mouse melanoma metastases and growth by D-penicillamine,”Laboratory Investigation, 21(5):434-438, 1969.
Kanatzidis and Coucouvanis, “Structure of Bis(tetraethylammonium) tetrathiomolybdte(VI), 2C8H20N+MoS42-,”Acta Cryst., C39:835-838, 1983.
Lee et al., “The Treatment of Wilson's Disease with Zinc VII. Protection of the Liver for Copper Toxicity by Zinc Induced Metallothionein in a Rat Model,”J. Lab. Clin. Med., 114:639-645, 1989.
Marshall et al., “Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer,”Clin. Cancer Res., 3:2347-2354, 1997.
Merajver et al., “Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice,”Proceedings of Special AACR Conference on Angiogenesis and Cancer, Abstract #B-11, Jan. 22-24, 1998.
Merajver, “Phase I study of tetrathymolybdate in metastatic cancer,” NIH Grant No. 5R03CA77122-02.
Mills et al., “Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats,”J. Inorg. Biochem., 14:189, 1981.
Mills et al., “Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate,”J. Inorg. Biochem., 14: 163, 1981.
Parke et al., “Characterization and quantification of copper sulfate-induced vascularization of the robbit cornea,”Am. J. Pathol., 130:173-178, 1988.
Patstone and Maher, “Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors,”J. Biol. Chem., 271:3343-3346, 1996.
Brem “Angiogenesis and cancer control: From concept to therapeutic trail,”Cancer Control, 6(5):436-458, 1999.
Brewer and Merajver, “Treatment of metastatic cancer with the anticopper antiangiogenenic drug tetrathiomolybdate,”J. Invest. Med., 47(7):223A, 1999.
Brewer et al., “Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study,”Clin. Canc. Res., 6(1):1-10, 2000.
International Search Report dated Jul. 4, 2000 (PCT/US99/20374; 4100.001010).
Merajver, “A Phase I study of oral tetrathiomolybdate (TM) as a decoppering and anti-angiogenesis agent for metastatic cancer,” From the Internet at website http://www.cancer.med.umich.edu/cgi-bin/protocol?9708—701, 1998.
Sergeant and Johnson, “Iron and copper requirements for proliferation and differentiation of a human promyelocytic leukemia cell line (HL-60),”J. Cell. Physiol., 163:477-485, 1995.
Shah et al., “Circular dichroism of carbohydrate-molybdate complexes,”Stud. Nat. Prod. Chem., 15:423-438, 1995.
Vine, et al. “Tetrathiomolybdate as an Antiangiogenesis Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration,” Trans. Am. Ophthalmol. Soc. vol. 100:73-77 (2002).
Brem et al., “Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic colactor,”Am. J. Pathol., 137(5):1121-1142, 1990.
Brem et al., “Tetrathiomolybdate, a chelator of copper, reduces intracerebral peritumoral edema in rats,”Proceeding of the American Association for Cancer Research, 33:76, Abstract 455, 1992.
Bremner et al., “Copper metabolism in rats given di-or trithiomolybdates,”J. Inorg. Biochem., 16: 109, 1982.
Brewer and Yuzbasiyan-Gurkan, “Wilson Disease,”Medicine, 71(3):139-164, 1992.
Brewer and Yuzbasiyan-Gurkan, “Wilson's Disease,” In:Textbook of Clinical Neuropharmocology and Therapeutics, 2nd Edition, Klawans et al., Eds., Raven Press, New York, pp. 191-205, 1992.
Brewer and Yuzbasiyan-Gurkan, “Wilson's disease: an update, with emphasis on new approaches to treatment,”Dig. Dis., 7(4):178-193, 1989.
Brewer, “Interactions of zinc and molybdenm with copper in therapy of Wilson's disease,”Nutr., 11(1 Suppl):114-116, 1995.
Brewer, “Practical recommendations and new therapies for Wilson's disease,”Drugs, 50(2):240-249, 1995.
Brewer, “Thiomolybdates in the treatment of Wilson's disease,”Arch. Neurol., 49: 132-133, 1992.
Brewer, “Zinc in the Treatment of Wilson's Disease,”Nutrition and the M.D.19(12): 1993.
Brewer et al., “Treatment of Wilson's disease with ammonium tetrathiomolybdate. I Initial therapy in 17 neurologically affected patients,”Arch. Neurol., 51(6):545-554, 1994.
Brewer et al., “Use of zinc acetate to treat copper toxicosis in dogs,”JAVMA201:564-568, 1992.
Brewer et al., “Treatment of Wilson's Disease with zinc XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis,”J. Lab. Clin. Med., 123:849-858, 1994.
Brewer et al., “Initial therapy of Wilson's Disease patients with tetrathiomolybdate,”Arch. Neurol., 48(1):42-47, 1991.
Brewer et al., “Treatment of
Brewer George J.
Coucouvanis Dimitri
Merajver Sofia D.
Maier Leigh C
Marshall & Gerstein & Borun LLP
The Regents of The University of Michigan
LandOfFree
Methods and compositions for the treatment of angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of angiogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001235